- Home
- CRDF vs DMAC Comparison
CRDF vs DMAC Comparison
Compare CRDF & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- DMAC
- Stock Information
- Founded
- CRDF 1999
- DMAC 2000
- Country
- CRDF United States
- DMAC United States
- Employees
- CRDF N/A
- DMAC N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- DMAC Health Care
- Exchange
- CRDF Nasdaq
- DMAC Nasdaq
- Market Cap
- CRDF 169.6M
- DMAC 178.0M
- IPO Year
- CRDF N/A
- DMAC N/A
- Fundamental
- Price
- CRDF $3.35
- DMAC $4.17
- Analyst Decision
- CRDF Strong Buy
- DMAC Strong Buy
- Analyst Count
- CRDF 4
- DMAC 2
- Target Price
- CRDF $12.25
- DMAC $8.00
- AVG Volume (30 Days)
- CRDF 874.0K
- DMAC 97.3K
- Earning Date
- CRDF 05-08-2025
- DMAC 05-13-2025
- Dividend Yield
- CRDF N/A
- DMAC N/A
- EPS Growth
- CRDF N/A
- DMAC N/A
- EPS
- CRDF N/A
- DMAC N/A
- Revenue
- CRDF $587,000.00
- DMAC N/A
- Revenue This Year
- CRDF N/A
- DMAC N/A
- Revenue Next Year
- CRDF N/A
- DMAC N/A
- P/E Ratio
- CRDF N/A
- DMAC N/A
- Revenue Growth
- CRDF N/A
- DMAC N/A
- 52 Week Low
- CRDF $2.01
- DMAC $2.14
- 52 Week High
- CRDF $5.64
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- CRDF 63.95
- DMAC 53.13
- Support Level
- CRDF $2.81
- DMAC $4.00
- Resistance Level
- CRDF $3.08
- DMAC $4.33
- Average True Range (ATR)
- CRDF 0.20
- DMAC 0.28
- MACD
- CRDF 0.08
- DMAC 0.02
- Stochastic Oscillator
- CRDF 76.53
- DMAC 58.57
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.